Omeros Stock (NASDAQ:OMER)
Previous Close
$10.11
52W Range
$2.61 - $13.60
50D Avg
$7.05
200D Avg
$4.69
Market Cap
$607.89M
Avg Vol (3M)
$910.10K
Beta
1.48
Div Yield
-
OMER Company Profile
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
OMER Performance
Peer Comparison
Ticker | Company |
---|---|
RVMD | Revolution Medicines, Inc. |
BMEA | Biomea Fusion, Inc. |
DAWN | Day One Biopharmaceuticals, Inc. |
STOK | Stoke Therapeutics, Inc. |
RNA | Avidity Biosciences, Inc. |
LGND | Ligand Pharmaceuticals Incorporated |
ARQT | Arcutis Biotherapeutics, Inc. |
CNTB | Connect Biopharma Holdings Limited |
AKRO | Akero Therapeutics, Inc. |
GOSS | Gossamer Bio, Inc. |
ORIC | ORIC Pharmaceuticals, Inc. |
CRNX | Crinetics Pharmaceuticals, Inc. |
DSGN | Design Therapeutics, Inc. |
FOLD | Amicus Therapeutics, Inc. |
PTGX | Protagonist Therapeutics, Inc. |
LYEL | Lyell Immunopharma, Inc. |
PASG | Passage Bio, Inc. |
ENTA | Enanta Pharmaceuticals, Inc. |
MIRM | Mirum Pharmaceuticals, Inc. |